BHVN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 20:41):

Stats
Šios dienos apimtis	289 502
Vidutinė apimtis	1.35M
Rinkos kapitalizacija	3.33B
EPS	$0 ( 2024-03-28 )
Kita pelno data	( $-1.500 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.11
ATR14	$0.0580 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Bailey Gregory	Buy	25 503	Common Shares
2024-04-22	Bailey Gregory	Buy	48 780	Common Shares
2024-04-22	Childs John W	Buy	97 560	Common Shares
2024-04-22	Childs John W	Buy	73 170	Common Shares
2024-04-22	Childs John W	Buy	24 391	Common Shares

INSIDER POWER
96.70
Last 99 transactions
Buy: 15 309 473 \| Sell: 296 589

Tūris Koreliacija

Ilgas: -0.10 (neutral)

Trumpas: 0.44 (neutral)

Signal:(75.382) Neutral

Biohaven Pharmaceutical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
THD	0.906
KB	0.888
SHG	0.882
NUVB	0.877
BKF	0.871
MX	0.866
YINN	0.866
RAYC	0.862
HBI	0.859
EDC	0.858

10 Labiausiai neigiamai susiję koreliacijos
CMO	-0.872
CSLT	-0.808

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Biohaven Pharmaceutical Koreliacija - Valiuta/Žaliavos

-0.15
( neutral )

-0.33
( neutral )

-0.66
( moderate negative )

-0.07
( neutral )

-0.29
( neutral )

0.47
( neutral )

Biohaven Pharmaceutical Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-3.37M (0.00 %)
EPS:	$-5.73

FY	2023
Pajamos:	$0
Bruto pelnas:	$-3.37M (0.00 %)
EPS:	$-5.73

FY	2022
Pajamos:	$0
Bruto pelnas:	$-1.39M (0.00 %)
EPS:	$-12.75

Financial Reports:

No articles found.

Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.